Company Filing History:
Years Active: 2012
Title: An Insight into Inventor David Jonas Persson
Introduction
David Jonas Persson, an innovative inventor located in Perstorp, Sweden, is recognized for his contributions to medicinal chemistry. He has made significant strides in the development of hydantoin derivatives, which hold promise as metalloproteinase inhibitors.
Latest Patents
David Jonas Persson holds a patent for "Hydantoin derivatives useful as metalloproteinase inhibitors." This patent outlines a specific formula where R is a (2-4C)alkyl that is substituted by two or more fluorine groups, and R is methyl or ethyl, including pharmaceutical acceptable salts. The patent also describes processes for their preparation, pharmaceutical compositions containing these compounds, and their use in treating diseases or medical conditions mediated by metalloproteinase enzymes.
Career Highlights
David is currently employed at AstraZeneca AB, a prominent company in the pharmaceutical industry known for its commitment to innovation in drug development. His work focuses on creating therapeutic solutions that improve patient outcomes by targeting specific biological pathways.
Collaborations
Throughout his career, David has collaborated with skilled professionals, including his coworker David Waterson. These collaborations enhance the research environment and foster innovation, enabling them to make advancements in the field of pharmaceutical science.
Conclusion
David Jonas Persson is an exemplary inventor whose work in hydantoin derivatives exemplifies the intersection of innovation and pharmaceutical development. His contributions at AstraZeneca AB continue to impact the treatment of diseases, showcasing the importance of ongoing research in healthcare.